吲哚菁绿血管造影在乳房切除术后乳房再造中的成本效益
单中心回顾性研究比较295例使用吲哚菁绿血管造影(ICGA)与228例未使用ICGA的植入物乳房再造,ICGA使缺血并发症率从14.9%降至8.8%,净节省220,088澳元,增量成本效用比为每质量调整生命年656澳元,作者认为在澳大利亚背景下常规使用ICGA具有成本效益。
要点
- ICGA使植入物乳房再造缺血并发症率从14.9%降至8.8%。
- 预防18例缺血并发症,净节省220,088澳元,需318例使用ICGA才能收支平衡。
- 决策模型显示ICGA每质量调整生命年增量成本为656澳元。
核心结论
- 在澳大利亚背景下,植入物乳房再造中常规使用ICGA是减少缺血并发症的成本效益干预。
- ICGA使用与额外获得1.77年完美健康相关,每年多花费656澳元。
研究设计与样本
- 单中心回顾性研究,纳入2015年至2020年295例使用ICGA的植入物乳房再造与228例未使用ICGA的再造进行对比。
- 成本采用Medicare项目编号和微观成本分析法计算,并进行收支平衡点分析和成本效用分析。
主要发现
- 使用ICGA的295例乳房再造总成本为164,657澳元,治疗一例缺血并发症的平均成本为21,375澳元。
- ICGA使缺血并发症率从14.9%降至8.8%,预防了18例乳房缺血并发症。
- 总成本节省384,745澳元,净节省220,088澳元。
- 需要318例使用ICGA才能达到收支平衡。
- 决策模型显示基线成本差为1,179澳元,质量调整生命年差为1.77,增量成本效用比为每质量调整生命年656澳元,支持ICGA。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mastectomy skin flap necrosis is a major complication of skin- or nipple-sparing mastectomy. Indocyanine green angiography (ICGA) is a novel technology that can identify flaps at risk of necrosis, but there is paucity of cost-effectiveness data particularly in the Australian context. We evaluated its cost-effectiveness in breast reconstruction surgery. METHODS: Single-institution retrospective study of 295 implant-based breast reconstructions using ICGA compared with 228 reconstructions without ICGA from 2015 to 2020. Costs were calculated using Medicare item numbers and micro-costing analysis. Break-even point analysis determined the number needed to break-even. Cost-utility analysis compared probabilities of ischaemic complications and utility estimates derived from surveys of surgeons to fit into a decision model. RESULTS: There were 295 breast reconstructions using ICGA with a total cost of AU$164,657. The average cost of treating an ischaemic complication was AU$21,375. Use of ICGA reduced the ischaemic complication rate from 14.9% to 8.8%. Ischaemic complications were prevented in 18 breasts resulting in gross cost savings of AU$384,745 and net savings of AU$220,088. Three hundred eighteen cases using ICGA are needed to break-even. The decision model demonstrated a baseline cost difference of AU$1,179, a quality-adjusted life-years (QALY) difference of 1.77, and an incremental cost-utility ratio (ICUR) of AU$656 per QALY favouring ICGA. CONCLUSIONS: Routine use of ICGA during implant-based breast reconstruction is a cost-effective intervention for the reduction of ischaemic complications in the Australian setting. ICGA use was associated with a gain of 1.77 additional years of perfect health at a cost of AU$656 more per year.
引用
- Nguyen CL, Dayaratna N, Comerford AP, et al. Cost-effectiveness of indocyanine green angiography in postmastectomy breast reconstruction. J Plast Reconstr Aesthet Surg. 2022. PMID: 35710777. doi:10.1016/j.bjps.2022.04.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。